• Researcher Profile

    Anthony V. D'Amico, MD, PhD

    Anthony V. D'Amico, MD, PhD

    Top Doctor

    Chief, Division of Genitourinary Radiation Oncology
    Institute Physician

    Professor of Radiation Oncology, Harvard Medical School


    Genitourinary Oncology
    Radiation Oncology

    Office phone: 617-732-8821
    Fax: 617-975-0932

    Preferred contact method: office phone

    View Physician Profile

    Research Departments

    Medical Oncology

    Radiation Oncology


    Prostate cancer, Bladder cancer, Testicular cancer, Renal cancer

    Brigham and Women's Hospital
    75 Francis Street
    ASB1 L2
    Boston, MA 02215


    Dr. D'Amico is a professor of Radiation Oncology at Harvard Medical School and is the chief of Genitourinary Radiation Oncology at the Brigham and Women's Hospital and Dana-Farber Cancer Institute. He received his PhD in Radiation Physics from the Massachusetts Institute of Technology in 1986, and then his MD from the University of Pennsylvania in 1990, where he also served as a resident and then chief resident in 1994. He has gained international recognition for his work in detection, staging, and treatment of prostate cancer with over 140 peer-reviewed publications, and has co-edited four textbooks in Urologic Oncology. His prostate cancer research is funded by federal grants from the NIH, NCI, DOD and MA DPH.

    Select Publications

    • D'Amico AV, Tempany CM, Cormack R, Hata N, Jinzaki M, Tuncali K, Weinstein M, Richie JP. Transperineal magnetic resonance image guided prostate biopsy. J Urol 2000; 164:385-387.
    • D'Amico AV, Cormack R, Kumar S, Tempany CM. Real-time magnetic resonance imaging-guided brachytherapy in the treatment of selected patients with clincially localized prostate cancer. J Endourology 2000; 14:367-370.
    • D'Amico AV, Schultz D, Schneider L, Hurwitz M, Kantoff PW, Richie JP. Comparing prostate specific antigen outcomes after different types of radiotherapy management of clinically localized prostate cancer highlights the importance of controlling for established prognostic factors. J Urol 2000; 163:1797-1801.
    • D'Amico AV, Weinstein M, Li X, Richie JP, Fujimoto J. Optical coherence tomography as a method for identifying benign and malignant microscopic structures in the prostate gland. Urology 2000; 55:783-787.
    • D'Amico AV, Whittington R, Malkowicz SB, Schnall M, Schultz D, Cote K. Tomaszewski JE, Wein A. Endorectal magnetic resonance imaging as a predictor of biochemical outcome following radical prostatectomy for men with clinically localized prostate cancer. J Urol 2000; 164:759-763.
    • D'Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen MH, Hurwitz M, Kantoff P, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant therapy trials. J Clin Oncol 2000; 18:3240-3246.
    • D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, Wein A. Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason Score < 7. Cancer 2000; 88:2110-2115.
    • D'Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen MH, Art M, Tomaszewski JE, Wein A. The combination of the preoperative PSA level, biopsy Gleason score, percent positive biopsies and MRI T-stage to predicte early PSA failure in men with clinically localized prostate cancer. Urology 2000; 55:752-576.
View Researcher Directory
View Nurse Directory

Find a Clinical Trial

Support Cancer

Give Now